PCNU Phase I study in the North California Oncology Group.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009150:Mustard Compounds / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009150:Mustard Compounds; D009607:Nitrosourea Compounds; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea